M Farnier

Summary

Affiliation: Rond Point de la Nation
Country: France

Publications

  1. ncbi Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil)
    Michel Farnier
    , Dijon, France
    Am J Cardiol 91:238-40. 2003
  2. ncbi [New antilipemics: prospects]
    Michel Farnier
    Therapie 58:97-105. 2003
  3. ncbi Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)
    Michel Farnier
    , Dijon, France
    Am J Cardiol 92:794-7. 2003
  4. ncbi Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France
    Expert Opin Pharmacother 8:1345-52. 2007
  5. ncbi Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France
    Int J Cardiol 102:327-32. 2005
  6. ncbi Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia
    Michel Farnier
    Point Medical, Rond Point de la Nation, Dijon F 21 000, France
    Eur Heart J 26:897-905. 2005
  7. ncbi Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks
    Michel Farnier
    Point Medical, Rond Point de la Nation, Dijon, France
    Am J Cardiovasc Drugs 3:169-78. 2003
  8. ncbi [Hyperlipidemia in the elderly]
    M Farnier
    Presse Med 30:957-63. 2001
  9. ncbi Diabetes: statins, fibrates, or both?
    M Farnier
    Point Medical, Rond Point de la Nation, Dijon, F 21000, France
    Curr Atheroscler Rep 3:19-28. 2001
  10. ncbi Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group
    M Farnier
    Point Medical, Dijon, France
    Am J Cardiol 85:53-7. 2000

Detail Information

Publications28

  1. ncbi Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil)
    Michel Farnier
    , Dijon, France
    Am J Cardiol 91:238-40. 2003
  2. ncbi [New antilipemics: prospects]
    Michel Farnier
    Therapie 58:97-105. 2003
    ..Finally, the discovery of new specific lipoprotein receptors, such as the ABCA1 and SRB1 receptors, means that we can work towards developing new potential targets for pharmacological intervention...
  3. ncbi Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)
    Michel Farnier
    , Dijon, France
    Am J Cardiol 92:794-7. 2003
    ..The combination of fluvastatin and fibrates was well tolerated with no major safety concerns...
  4. ncbi Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France
    Expert Opin Pharmacother 8:1345-52. 2007
    ..Nevertheless, this combination therapy of ezetimibe plus fenofibrate seems particularly useful for patients with a poor response or intolerance to statin monotherapy...
  5. ncbi Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France
    Int J Cardiol 102:327-32. 2005
    ..60 mmol/l (100 mg/dl) in hypercholesterolemic patients with coronary heart disease (CHD)...
  6. ncbi Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia
    Michel Farnier
    Point Medical, Rond Point de la Nation, Dijon F 21 000, France
    Eur Heart J 26:897-905. 2005
    ..To examine the efficacy and safety of coadministered ezetimibe (EZE) with fenofibrate (FENO) in patients with mixed hyperlipidaemia...
  7. ncbi Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks
    Michel Farnier
    Point Medical, Rond Point de la Nation, Dijon, France
    Am J Cardiovasc Drugs 3:169-78. 2003
    ....
  8. ncbi [Hyperlipidemia in the elderly]
    M Farnier
    Presse Med 30:957-63. 2001
    ..Likewise, taking into account associated disease states and the increased risk of drug interactions, primary prevention regimens cannot be recommended except for elderly patients with a high overall cardiovascular risk...
  9. ncbi Diabetes: statins, fibrates, or both?
    M Farnier
    Point Medical, Rond Point de la Nation, Dijon, F 21000, France
    Curr Atheroscler Rep 3:19-28. 2001
    ..If lipid target values are not reached, a combination therapy can then be initiated, with close follow-up of potential side effects...
  10. ncbi Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group
    M Farnier
    Point Medical, Dijon, France
    Am J Cardiol 85:53-7. 2000
    ..In conclusion, the addition of fluvastatin to micronized fenofibrate results in substantial improvement in atherogenic plasma lipids and is well tolerated...
  11. ncbi Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study
    M Farnier
    Point Medical, Rond Point de Nation, Dijon, France
    Int J Clin Pract 63:547-59. 2009
    ..To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg vs. rosuvastatin (ROSUVA) 10 mg...
  12. ncbi [When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis]
    M Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon
    Arch Mal Coeur Vaiss 100:569-81. 2007
  13. ncbi Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment
    M Farnier
    Point Medical, Rond Point de la Nation, Dijon, France
    Am J Cardiol 82:47J-51J. 1998
    ..This study demonstrated that cerivastatin is a safe, well-tolerated, and effective treatment for lowering elevated LDL cholesterol and triglycerides in patients with mixed hyperlipidemia...
  14. ncbi Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia
    Michel Farnier
    Point Medical, Dijon, France
    Am Heart J 153:335.e1-8. 2007
    ..Mixed hyperlipidemia is characterized by elevated low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and TG-rich lipoprotein levels...
  15. ncbi [How to manage lipid profiles and their interpretation in patients with coronary heart disease?]
    Michel Farnier
    Endocrinologie maladies métaboliques, Point Medical, F 21000, Dijon, France
    Presse Med 38:958-63. 2009
    ..In coronary patients treated with a statin, management of abnormal levels of triglycerides and HDL-cholesterol is important to minimize the risk of recurrence...
  16. ncbi Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy
    Michel Farnier
    Point Medical, Dijon, France
    Am J Cardiol 106:787-92. 2010
    ....
  17. ncbi Ezetimibe in hypercholesterolaemia
    M Farnier
    , Dijon, France
    Int J Clin Pract 56:611-4. 2002
    ..This additive 18% reduction in LDL-C is achieved in one step compared with the three steps necessary with statin monotherapy...
  18. ncbi Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
    Michel Farnier
    Point Medical, Dijon, France
    Vasc Health Risk Manag 4:991-1000. 2008
    ..However, the role of fenofibrate-statin therapy and of other therapies involving fenofibrate in cardiovascular risk reduction strategies remains to be established...
  19. ncbi Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin
    Michel Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon, France
    Fundam Clin Pharmacol 21:27-8. 2007
    ..Ezetimibe/simvastatin offers an important treatment alternative to patients who respond inadequately even to high-dose statin therapy...
  20. ncbi VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate
    Michel Farnier
    Point Medical, Dijon, France
    J Lipid Res 49:2641-7. 2008
    ..Thus, ezetimibe/simvastatin + fenofibrate produced favorable effects on atherogenic lipoprotein subclasses in patients with mixed hyperlipidemia...
  21. ncbi Prevalence of low HDL-cholesterol in patients with cardiovascular risk factors: The ECHOS (Etude du Cholesterol HDL en Observationnel) French Survey
    M Farnier
    Point Medical, Dijon, France
    Int J Clin Pract 60:1166-71. 2006
    ..Our findings indicate that in France, the prevalence of low HDL-C remains relatively high, particularly for patients with obesity and HTG...
  22. ncbi [Dyslipidemia and abdominal obesity: therapeutic approaches (Part II)]
    M Farnier
    Point Medical, Dijon
    Arch Mal Coeur Vaiss 100:985-7, 990-1. 2007
    ..New therapeutic approaches are aimed directly at the excess visceral adipose tissue, and the CB1 receptor blockers are particularly promising for improving the overall lipid profile for patients with abdominal obesity...
  23. ncbi [Dyslipidemia and abdominal obesity: mechanisms and characteristics (Part I)]
    M Farnier
    Point Medical, Dijon
    Arch Mal Coeur Vaiss 100:979-84. 2007
    ..This excess adipose tissue seems to be the direct origin of the dyslipidemia associated with abdominal obesity, causing more free fatty acids to flow into the liver and contributing to insulin resistance...
  24. ncbi Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction
    Marianne Zeller
    Laboratory of Cardiovascular and Experimental Physiopathology and Pharmacology, Faculty of Medicine, University of Burgundy, Dijon, France
    Arch Intern Med 165:1192-8. 2005
    ....
  25. ncbi Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia
    Diane L Tribble
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Metabolism 57:796-801. 2008
    ....
  26. ncbi Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia
    James M McKenney
    National Clinical Research Inc, Richmond, Virginia 23294, USA
    J Am Coll Cardiol 47:1584-7. 2006
    ..This study sought to determine the long-term safety and efficacy of co-administered fenofibrate (FENO) and ezetimibe (EZE) in patients with mixed hyperlipidemia...
  27. ncbi Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH, USA
    Am J Cardiol 100:1387-96. 2007
    ..In conclusion, long-term treatment with rosuvastatin 40 mg is safe and effective in patients with severe hypercholesterolemia...
  28. ncbi [Hypercholesterolemia, the future of drug associations]
    James Shepherd
    Presse Med 33:1141-2. 2004